BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 25278593)

  • 1. The littlest patient.
    Couzin-Frankel J
    Science; 2014 Oct; 346(6205):24-7. PubMed ID: 25278593
    [No Abstract]   [Full Text] [Related]  

  • 2. Autophagy, p53, and pancreatic cancer.
    Iacobuzio-Donahue CA; Herman JM
    N Engl J Med; 2014 Apr; 370(14):1352-3. PubMed ID: 24693896
    [No Abstract]   [Full Text] [Related]  

  • 3. The KRAS-PDEδ interaction is a therapeutic target.
    Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells.
    Wang X; Zhao J; Huang J; Tang H; Yu S; Chen Y
    Biochem Biophys Res Commun; 2012 Aug; 425(1):51-7. PubMed ID: 22820191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
    Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
    Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse Models of Pancreatic Ductal Adenocarcinoma.
    Ponz-Sarvise M; Tuveson DA; Yu KH
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):609-17. PubMed ID: 26226900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetic aspects of pancreatic cancer].
    Grigor'eva IN; Efimova OV; Suvorova TS; Tov NL
    Eksp Klin Gastroenterol; 2014; (10):70-6. PubMed ID: 25911935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway.
    Xu W; Wang Z; Zhang W; Qian K; Li H; Kong D; Li Y; Tang Y
    Cancer Lett; 2015 Jan; 356(2 Pt B):613-27. PubMed ID: 25305448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection tools for pancreatic cancer.
    Schmidt C
    J Natl Cancer Inst; 2012 Aug; 104(15):1117-8. PubMed ID: 22851273
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of predictive markers in oncology: are phase 3 trials always required?
    Markman M
    Oncology; 2011; 81(1):1-2. PubMed ID: 21894048
    [No Abstract]   [Full Text] [Related]  

  • 12. Translational research in pancreatic cancer: KRAS and beyond.
    Boeck S; Ormanns S; Haas M; Bächmann S; Laubender RP; Siveke JT; Jung A; Kirchner T; Heinemann V
    Pancreas; 2014 Jan; 43(1):150-2. PubMed ID: 24326376
    [No Abstract]   [Full Text] [Related]  

  • 13. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress of targeted therapy related to K-ras mutation].
    Li ZW; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
    [No Abstract]   [Full Text] [Related]  

  • 15. Pancreatic cancer research matures.
    Nelson NJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1432-4. PubMed ID: 17895469
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.
    Reicher S; Boyar FZ; Albitar M; Sulcova V; Agersborg S; Nga V; Zhou Y; Li G; Venegas R; French SW; Chung DS; Stabile BE; Eysselein VE; Anguiano A
    Pancreas; 2011 Oct; 40(7):1057-62. PubMed ID: 21705950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy of pancreatic cancer targeting the K-Ras oncogene.
    Lisiansky V; Naumov I; Shapira S; Kazanov D; Starr A; Arber N; Kraus S
    Cancer Gene Ther; 2012 Dec; 19(12):862-9. PubMed ID: 23099885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing methods for the diagnosis of pancreatic cancer.
    Brugge WR
    J Clin Gastroenterol; 2007; 41(10):869-70. PubMed ID: 18090153
    [No Abstract]   [Full Text] [Related]  

  • 19. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What we have learned about pancreatic cancer from mouse models.
    Pérez-Mancera PA; Guerra C; Barbacid M; Tuveson DA
    Gastroenterology; 2012 May; 142(5):1079-92. PubMed ID: 22406637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.